Piper Sandler analyst David Westenberg lowered the firm’s price target on Neogen to $19 from $20 and keeps a Neutral rating on the shares. The analyst updated models in the animal health space.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NEOG: